Elunetirom

Clinical data
Other names	ABX-002; ABX002; MA-JD21; MA-JD-21
Routes of administration	Oral[1]
Drug class	Thyromimetic; Thyroid hormone receptor beta (TRβ) agonist
Identifiers
IUPAC name 2-[3,5-dichloro-4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]phenoxy]-N-methylacetamide
CAS Number	2156649-32-8
PubChem CID	132160637
DrugBank	DB18157
ChemSpider	129433137
UNII	QTW4WC4BRX
KEGG	D13273
ChEMBL	ChEMBL5314909
Chemical and physical data
Formula	C19H21Cl2NO3
Molar mass	382.28 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)C1=C(C=CC(=C1)CC2=C(C=C(C=C2Cl)OCC(=O)NC)Cl)O
InChI InChI=1S/C19H21Cl2NO3/c1-11(2)14-6-12(4-5-18(14)23)7-15-16(20)8-13(9-17(15)21)25-10-19(24)22-3/h4-6,8-9,11,23H,7,10H2,1-3H3,(H,22,24) Key:CQELSEDWYWTMDG-UHFFFAOYSA-N

Elunetirom, also known by its developmental code names ABX-002 and MA-JD21, is a thyroid hormone receptor agonist which is under development for the treatment of major depressive disorder, bipolar depression, multiple sclerosis, and adrenomyeloneuropathy.^[1][2] It is a prodrug of LL-340001 and acts as a potent, selective, and centrally penetrant agonist of the thyroid hormone receptor beta (TRβ).^[1][2] The drug produces psychoplastogenic effects similar to those of brain-derived neurotrophic factor (BDNF) in rodents.^[2] In addition, it has been found to improve cognitive impairment caused by old age or scopolamine treatment in rodents.^[2] Eunetirom is under development by Autobahn Therapeutics.^[1] As of December 2025, it is in phase 2 clinical trials for treatment of major depressive disorder and bipolar depression and is in the preclinical research stage of development for multiple sclerosis and adrenomyeloneuropathy.^[1]

See also

• Thyromimetic
• List of investigational antidepressants

References

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e